Acquisition Opportunity Identify collaboration or licensing opportunities with Epicore Biosystems, which now owns Eccrine Systems' sweat sensing IP and assets, to bring remote, non-invasive medication monitoring into pharma and clinical workflows.

Targeted Therapeutics Highlight markets where sweat-based monitoring supports precision dosing and adherence, including oncology, organ transplant immunosuppression, and opioid management, to tailor outreach to hospitals, clinics, and life science customers.

Strategic Partnerships Leverage past collaboration and investor interest with Maxim Ventures and corporate partners to approach device manufacturers, sensor integrators, and pharma companies for co-development and integration of sweat sensing tech.

Market Positioning Position as a cost‑effective, remote biomarker platform that can reduce the need for blood draws and enable continuous monitoring, aligning with telehealth and value-based care trends while acknowledging competitive wearable players.

IP Licensing Assess licensing or asset‑based deals for the underlying sensor technology and software stack, given ownership transfer, to quickly bring a differentiated sweat monitoring capability to healthcare providers and digital health platforms.